You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 遠大醫藥升逾5% 引入肝癌創新療法有望帶來收入和盈利貢獻
格隆匯 01-10 15:42
格隆匯1月10日丨遠大醫藥(0512.HK)今日股價明顯上漲,上午盤一度急漲超7%。現漲5.18%,報4.67港元,暫成交1704萬港元,最新總市值157.7億港元。日前國家衞生健康委員會醫政醫管局發佈了《原發性肝癌診療規範(2019年版)》。而就在不久前,公司聯手鼎暉資本收購澳洲sirtex公司,將其全球獨家治療惡性肝腫瘤的放射介入性醫療產品90Y微球療法——Y-90樹脂微球產品納入旗下,並推動Y-90樹脂微球在中國的註冊及落地工作。業內人士表示隨着國家對創新支持力度的增大,以及藥品器械審評審批提速等,該創新療法有望加速在國內上市。預期將為遠大醫藥帶來極為可觀的銷售收入和盈利貢獻。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account